Selected recent publications:
-
Romo de Vivar Chavez A, de Vera ME, Liang X, Lotze MT. The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma. Medical Oncology. 2009;26 Suppl 1:3-12. Epub 2009 Jan 16.
-
Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, Rutledge R, Lin B, Amoscato AA, Zeh HJ, Lotze MT. RAGE (Receptor for Advanced Glycation Endproducts), RAGE Ligands, and their role in Cancer and Inflammation. Journal of Translational Medicine. 2009 Mar 17;7(1):17.
-
Lotfi R, Schrezenmeier H, Lotze MT. Immunotherapy for cancer: promoting innate immunity. Frontiers in Bioscience. 2009 Jan 1;14:818-32.
-
Tang D, Kang R, Xiao W, Zhang H, Lotze MT, Wang H, Xiao X. Quercetin Prevents Lipopolysaccharide-induced HMGB1 Release and Proinflammatory Function. American Journal of Respiratory Cell and Molecular Biology. 2009 Mar 5.
-
Moschos SJ, Mandic M, Kirkwood JM, Storkus WJ, Lotze MT. Focus on FOCIS: interleukin 2 treatment associated autoimmunity. Clinical Immunology. 2008 May;127(2):123-9. Review.
-
Vakkila J, Demarco RA, Lotze MT. Coordinate NF-kappaB and STAT1 activation promotes development of myeloid type 1 dendritic cells. Scandinavian Journal of Immunology. 2008 Mar;67(3):260-9.
-
Lotfi R, Lotze MT. Eosinophils induce DC maturation, regulating immunity. Journal of Leukocyte Biology. 2008 Mar;83(3):456-60. Epub 2007 Nov 8.
-
Ostberg T, Wähämaa H, Palmblad K, Ito N, Stridh P, Shoshan M, Lotze MT, Harris HE, Andersson U. Oxaliplatin retains HMGB1 intranuclearly and ameliorates collagen type II-induced arthritis. Arthritis Research and Therapy. 2008;10(1):R1. Epub 2008 Jan 7.
-
Lotze MT, Zeh HJ, Rubartelli A, Sparvero LJ, Amoscato AA, Washburn NR, Devera ME, Liang X, Tör M, Billiar T. The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunological Reviews. 2007 Dec;220:60-81. Review.
-
Zetterström CK, Jiang W, Wähämaa H, Ostberg T, Aveberger AC, Schierbeck H, Lotze MT, Andersson U, Pisetsky DS, Erlandsson Harris H. Pivotal advance: inhibition of HMGB1 nuclear translocation as a mechanism for the anti-rheumatic effects of gold sodium thiomalate. Journal of Leukocyte Biology. 2008 Jan;83(1):31-8. Epub 2007 Oct 3.
-
Hikawa H, Lotze MT, Rosenblum WD. Induction of peripheral tolerance by local delivery of dendritic cell progenitors to cardiac allografts in a murine heterotopic heart transplantation model. General Thoracic and Cardiovascular Surgery. 2007 Aug;55(8):307-14.
-
Rubartelli A, Lotze MT. Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends in Immunology. 2007 Oct;28(10):429-36. Epub 2007 Sep 12.
-
Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, Anichini A. Interleukin-12: biological properties and clinical application. Clinical Cancer Research. 2007 Aug 15;13(16):4677-85. Review.
-
Dong Xda E, Ito N, Lotze MT, Demarco RA, Popovic P, Shand SH, Watkins S, Winikoff S, Brown CK, Bartlett DL, Zeh HJ 3rd. High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. Journal of Immunotherapy. 2007 Sep;30(6):596-606.
-
Atkins MB, Carbone D, Coukos G, Dhodapkar M, Ernstoff MS, Finke J, Gajewski TF, Gollob J, Lotze MT, Storkus W, Weiner LM. Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics. Journal of Immunotherapy. 2007 Sep;30(6):577-90. Review.
CONTACT INFORMATION
Dr. Michael T. LotzePhone: (412) 624-9375
Email: lotzemt@upmc.edu